表紙
市場調査レポート

世界の大腸がん治療薬市場の製品・パイプライン分析:標的治療と免疫学を組み合わせ、次の段階へ

Product and Pipeline Analysis of the Global Colorectal Cancer Market - Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level

発行 Frost & Sullivan 商品コード 339441
出版日 ページ情報 英文 105 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
世界の大腸がん治療薬市場の製品・パイプライン分析:標的治療と免疫学を組み合わせ、次の段階へ Product and Pipeline Analysis of the Global Colorectal Cancer Market - Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level
出版日: 2015年09月09日 ページ情報: 英文 105 Pages
概要

当レポートでは、世界の大腸がん (CRC) 治療薬市場について調査分析し、市場概要、収益予測、競合情勢、上市製品、パイプライン薬の分析、最近の承認薬・後期パイプライン薬候補などについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査手法と範囲

第3章 市場概要

  • 市場概要:治療の種類 (開発中)
  • 市場概要:世界のCRCの発症率
  • 市場概要:米国の発症率:年齢別、性別
  • 市場概要:バイオマーカーの種類区分
  • 市場概要:主なM&A、パートナーシップ
  • 市場概要:最近の発展動向

第4章 収益予測

  • 世界のCRC市場:収益予測
  • 収益予測の考察

第5章 競合情勢

  • 競合情勢の概要
  • 競合情勢:フェーズ3から発売まで
  • 競合情勢:フェーズ2
  • 競合情勢:フェーズ1

第6章 上市製品

  • 主な上市製品

第7章 パイプライン薬の分析

  • パイプラインの概要:フェーズ3
  • パイプラインの概要:フェーズ2
  • パイプラインの概要:フェーズ1
  • 競合情勢:ピボタル試験 (フェーズ3)
  • 主なイベントのタイムライン
  • 特許失効
  • パイプラインの考察

第8章 最近の承認薬・後期パイプライン薬候補の製品ダッシュボード

  • 製品ダッシュボード - Avastin (Bevacizumab) :Genentech Inc. (Roche Group)
  • 製品ダッシュボード - BBI503:Boston Biomedical
  • 製品ダッシュボード - Cyramza (ramicirumab):Eli Lilly
  • 製品ダッシュボード - Erbitux (cetuximab):Eli Lilly/BMS/Merck
  • 製品ダッシュボード - Imprime PGG:Biothera
  • 製品ダッシュボード - Lonsurf (TAS-102):大鵬薬品 (大塚製薬)
  • 製品ダッシュボード - MGN1703:Mologen
  • 製品ダッシュボード - Nintedanib (BIBF-1120、OFEV):Boehringer Ingelheim
  • 製品ダッシュボード - Stivarga (regorafenib):Bayer/Onyx Pharmaceuticals
  • 製品ダッシュボード - Zaltrap (aflibercept):Sanofi

第9章 結論

第10章 Frost & Sullivanについて

目次
Product Code: M986-52

Research Overview

This Frost & Sullivan research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research, Frost & Sullivan's expert analysts thoroughly examine the following modalities:

  • targeted therapies
  • cytotoxics
  • cancer vaccines
  • other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).

The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.

Market Overview

Strong drug pipeline continues to expand

The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.

Colorectal cancer care edges toward personalisation

With the increasing focus on treatment outcomes, the market for colorectal cancer is undoubtedly moving toward personalised modes of care. Targeted solutions dominate the colorectal cancer pipeline, accounting for 60 percent of the treatment modalities under production. The improved understanding of the molecular mechanisms of colorectal cancer will facilitate the identification of newer targets and give rise to multi-targeted therapies. Meanwhile, biomarker testing is expected to become the standard of care, as it can help select a targeted therapy for a patient's particular need (predictive biomarkers), as well as define the patient's specific tumour type (prognostic biomarkers).

Beyond effective care delivery, employing targeted solutions will greatly enhance the reimbursement potential. By treating patients that are most likely to respond to a particular therapy, healthcare givers will be able to better justify the high costs to insurance firms and government payers. Therefore, clinical trials of targeted therapy drugs using biomarkers as surrogate endpoints will boost their chances of approval. Ultimately, the use of targeted remedies, coupled with immunotherapy, though complicated, will bridge the gap between the current need and future scope of colorectal cancer treatment globally.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Executive Summary (continued)
  • 4. Executive Summary (continued)
  • 5. Executive Summary (continued)
  • 6. Physician Treatment Guidelines-Lines of Therapy
  • 7. Key Trends
  • 8. Market Opportunities
  • 9. Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. MARKET OVERVIEW

Market Overview

  • 1. Market Overview-Types of Treatment in Development
  • 2. Market Overview-Global Incidences of CRC
  • 3. Market Overview-US Incidence Rates by Year and Sex
  • 4. Market Overview-Biomarker Type Segmentation
  • 5. Market Overview-Key Mergers, Acquisitions, and Partnerships
  • 6. Market Overview-Recent Developments

4. REVENUE FORECAST

Revenue Forecast

  • 1. Global CRC Market-Revenue Forecast
  • 2. Revenue Forecast Discussion
  • 3. Revenue Forecast Discussion (continued)
  • 4. Revenue Forecast Discussion (continued)

5. COMPETITIVE LANDSCAPE

Competitive Landscape

  • 1. Competitive Landscape Overview
  • 2. Competitive Landscape-Phase III to Launch
  • 3. Competitive Landscape-Phase II
  • 4. Competitive Landscape-Phase I

6. MARKETED PRODUCTS

Marketed Products

  • 1. Key Marketed Products
  • 2. Key Marketed Products (continued)
  • 3. Key Marketed Products (continued)
  • 4. Key Marketed Products (continued)

7. PIPELINE DRUGS ANALYSIS

Pipeline Drugs Analysis

  • 1. Pipeline Synopsis-Phase III
  • 2. Pipeline Synopsis-Phase III (continued)
  • 3. Pipeline Synopsis-Phase III (continued)
  • 4. Pipeline Synopsis-Phase III (continued)
  • 5. Pipeline Synopsis-Phase III (continued)
  • 6. Pipeline Synopsis-Phase II
  • 7. Pipeline Synopsis-Phase II (continued)
  • 8. Pipeline Synopsis-Phase II (continued)
  • 9. Pipeline Synopsis-Phase II (continued)
  • 10. Pipeline Synopsis-Phase II (continued)
  • 11. Pipeline Synopsis-Phase II (continued)
  • 12. Pipeline Synopsis-Phase II (continued)
  • 13. Pipeline Synopsis-Phase II (continued)
  • 14. Pipeline Synopsis-Phase II (continued)
  • 15. Pipeline Synopsis-Phase II (continued)
  • 16. Pipeline Synopsis-Phase II (continued)
  • 17. Pipeline Synopsis-Phase II (continued)
  • 18. Pipeline Synopsis-Phase II (continued)
  • 19. Pipeline Synopsis-Phase II (continued)
  • 20. Pipeline Synopsis-Phase I
  • 21. Pipeline Synopsis-Phase I (continued)
  • 22. Pipeline Synopsis-Phase I (continued)
  • 23. Pipeline Synopsis-Phase I (continued)
  • 24. Pipeline Synopsis-Phase I (continued)
  • 25. Pipeline Synopsis-Phase I (continued)
  • 26. Competitive Landscape-Pivotal Phase III Trials
  • 27. Timeline of Key Events
  • 28. Patent Expirations
  • 29. Pipeline Discussion
  • 30. Pipeline Discussion (continued)

8. PRODUCT DASHBOARD OF RECENTLY APPROVED DRUGS AND LATE-STAGE PIPELINE DRUG CANDIDATES

Product Dashboard of Recently Approved Drugs and Late-stage Pipeline Drug Candidates

  • 1. Product Dashboard: Avastin (Bevacizumab)-Genentech Inc. (Roche Group)
  • 2. Avastin (Genentech, Roche)-SWOT Analysis
  • 3. Product Dashboard-BBI503: Boston Biomedical
  • 4. BBI503 (Boston Biomedical)-SWOT Analysis
  • 5. Product Dashboard-Cyramza (ramicirumab): Eli Lilly
  • 6. Cyramza (ramicirumab) (Eli Lilly)-SWOT Analysis
  • 7. Product Dashboard-Erbitux (cetuximab): Eli Lilly/BMS/Merck
  • 8. Erbitux (Eli Lilly, BMS, and Merck)-SWOT Analysis
  • 9. Product Dashboard-Imprime PGG: Biothera
  • 10. Imprime PGG (Biothera)-SWOT Analysis
  • 11. Product Dashboard-Lonsurf (TAS-102): Taiho (Otsuka)
  • 12. Lonsurf (TAS-102) (Taiho, Otsuka)-SWOT Analysis
  • 13. Product Dashboard-MGN1703: Mologen
  • 14. MGN1703 (Mologen)-SWOT Analysis
  • 15. Product Dashboard-Nintedanib (BIBF-1120, OFEV): Boehringer Ingelheim
  • 16. Nintedanib (BIBF-1120, OFEV) (BI)-SWOT Analysis
  • 17. Product Dashboard-Stivarga (regorafenib): Bayer/Onyx Pharmaceuticals
  • 18. Stivarga (Bayer, Onyx)-SWOT Analysis
  • 19. Product Dashboard-Zaltrap (aflibercept): Sanofi
  • 20. Zaltrap (aflibercept) (Sanofi)-SWOT Analysis

9. CONCLUSIONS

Conclusions

  • 1. Conclusions
  • 2. Conclusions (continued)
  • 3. The Last Word-3 Big Predictions
  • 4. The Last Word-Discussion
  • 5. Legal Disclaimer

10. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top